81-84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations

Join Fractyl Health for a virtual event to discuss one-year results from the REMAIN-1 Midpoint Cohort evaluating Revita, a one-time, minimally invasive endoscopic procedure designed for durable weight maintenance following discontinuation of GLP-1-based therapy. The event will feature presentations by members of Fractyl Health’s management team, along with Adarsh M. Thaker, MD (UCLA Health), who will provide clinical perspective on the post-GLP-1 weight maintenance landscape and Revita’s clinical results.

Management will also review next steps for the REMAIN-1 program, including topline 6-month randomized data from the REMAIN-1 Pivotal Cohort, which is anticipated in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026.

A live question and answer session will follow the formal presentations.